Adaptive pathways and PRIME: A true acceleration of drug development and approval?

The European Medicines Agency (EMA) has launched two initiatives - Adaptive Pathways and PRIME (PRIorityMEdicines) - to improve timely access for patients to new and promising medicines. How do this initiatives work and will they truly accelerate drug development and approval or should they rather be perceived as old wine in new tubes? Read more from Dr. Diane Seimetz, instructor at Goethe Business School.